Hepatitis C and Blood Transfusion: Risk, Screening, and History

Hepatitis C virus (HCV) stands as the nation’s most common blood-borne infection — and for decades, it spread silently through blood transfusions before anyone knew how to test for it. Understanding HCV’s history, risk factors, and current status is essential for anyone who received blood products before the 1990s, belongs to a high-risk group, or simply wants to understand blood safety.

What Is Hepatitis C and Why Is It a Blood Emergency?

Hepatitis C is one of five identified hepatitis viruses (A, B, C, D, and E). Unlike hepatitis A and B, HCV has no vaccine. It specifically attacks the liver, causing inflammation that progresses silently over years — often without any symptoms until serious damage has occurred.

The virus affects approximately 4 million Americans in chronic form and causes 8,000–10,000 deaths annually in the United States. HCV is the primary reason for liver transplantation in America. The consequences of untreated infection — cirrhosis, liver cancer, liver failure — make it one of the most serious blood-borne pathogens known.

How Does Hepatitis C Spread Through Blood?

HCV is transmitted predominantly through direct blood-to-blood contact. Unlike HIV, which requires larger fluid exposures, HCV is highly efficient at transmission via small blood exposures — making shared needles, contaminated medical equipment, and (historically) untested blood transfusions effective routes of infection.

Primary transmission routes include:

• Sharing needles or syringes during injection drug use
• Receiving blood transfusions or organ transplants before 1992
• Needlestick injuries in healthcare settings
• Birth from an HCV-infected mother
• Sharing personal items with blood exposure (razors, nail clippers)
• In some cases, sexual transmission (lower risk, but real)

Hepatitis C is not spread through casual contact, sharing food or water, hugging, or coughing.

Who Is at Highest Risk for Hepatitis C?

Transfusion Recipients Before June 1992

This is the single most important high-risk group for blood transfusion-transmitted HCV. Routine blood screening for hepatitis C did not begin until June 1992 in the United States. Before that date, hundreds of thousands of people acquired HCV from transfusions with no way to detect it.

The U.S. government estimated that approximately 300,000 people contracted hepatitis C from blood transfusions before 1990 screening became available. A 1996 Congressional report called for direct notification to all those patients — a task that proved logistically difficult.

Injection Drug Users

Sharing needles remains the most common current route of HCV transmission in the United States. A single shared needle can transfer enough blood to establish infection.

Healthcare Workers

Needlestick injuries expose healthcare workers to patient blood. The occupational risk is real but manageable with universal precautions — proper glove use, safety needles, and exposure protocols.

Patients With Hemophilia

People with hemophilia required frequent infusions of clotting factor concentrates, which were historically derived from large plasma pools (sometimes 20,000–60,000 donors per batch). Before viral inactivation techniques were developed, a single contaminated unit could infect the entire pool. Thousands of hemophiliacs contracted HCV — and HIV — from factor products in the 1970s and 1980s.

Veterans

Veterans face hepatitis C rates 4–5 times higher than the general civilian population. A Department of Defense study found that 8–10% of veterans in one survey tested positive for HCV. The elevated risk is attributed to battlefield blood exposures, pre-1992 blood transfusions in military medical settings, and, in some populations, injection drug use.

A DoD assessment of active duty personnel found an overall HCV infection rate of 0.48% — more than three times lower than the 1.8% general population rate. However, older service members (35+) had rates of 1.7%, reflecting pre-screening era exposure.

Other High-Risk Groups

• Patients with chronic renal failure or undergoing long-term hemodialysis
• Individuals undergoing chemotherapy
• Solid-organ transplant recipients from HCV-positive donors
• Infants born to HCV-infected mothers (vertical transmission rate: 5–6%)
• Women who received Rh-factor transfusions during childbirth or C-sections before 1992

What Changed in 1992? The Screening Breakthrough

Before 1990, there was no reliable test for hepatitis C. The virus was identified in 1989, and the first anti-HCV screening test was introduced for blood donations in 1990 — but early tests had limited sensitivity. By June 1992, improved second-generation tests were in use across U.S. blood centers, dramatically reducing transfusion-transmitted HCV.

The current estimated risk of contracting HCV from a screened blood transfusion is approximately 1 in 121,000 per unit transfused. This is far lower than the pre-screening era, when infected donations were common and undetectable.

Since 1999, nucleic acid amplification testing (NAT) has further shortened the “window period” between infection and detectability — catching HCV in donated blood even before antibodies develop.

How Is Hepatitis C Managed Today?

Screening and Detection

The CDC recommends one-time HCV testing for all adults aged 18–79, regardless of risk factors. Anyone in a high-risk group should be tested regularly. A blood test for HCV antibodies is the standard first step; a positive result is confirmed with a viral load test (PCR).

Treatment: From Difficult to Curative

Until the mid-2010s, HCV treatment involved prolonged interferon-based therapy with serious side effects and success rates of 40–80% at best. Direct-acting antiviral (DAA) drugs — approved starting in 2013 and now widely available — cure more than 95% of patients in 8–12 weeks with minimal side effects. Treatment is now recommended for essentially all patients with chronic HCV.

The “Look-Back” Program

The U.S. Public Health Service implemented a “look-back” program to notify people who received blood from donors who later tested HCV-positive. Blood centers contacted hospitals, which were supposed to notify recipients. Results were mixed — tracking down patients from transfusions decades earlier proved difficult.

What Does HCV Mean for the Blood Supply Today?

The U.S. blood supply is currently screened with multiple layers of protection — donor questionnaires, anti-HCV antibody testing, and NAT testing. The FDA blood safety framework mandates these tests on every donated unit.

Despite improvements, the blood supply is not risk-free. Clerical errors, the window period before infection is detectable, and emerging pathogens remain ongoing concerns. The blood supply safety overview covers the full scope of protections and their documented limitations.

Anyone with HCV risk factors — especially those who received transfusions before 1992 — should discuss testing with a physician. With curative treatments now available, there is no reason to delay diagnosis.